Literature DB >> 8985222

New murine model of bronchopneumonia due to cell-bound Haemophilus influenzae.

S Miyazaki1, T Nunoya, T Matsumoto, K Tateda, K Yamaguchi.   

Abstract

This murine model of nontypeable (unencapsulated) Haemophilus influenzae (NTHI) bronchopneumonia used organisms bound to mouse fetal lung (MFL) cells as an inoculum. Pretreatment of the mice with 40 microL of 1% formalin 3 days before intranasal instillation of the bacteria was necessary to allow infection. The number of NTHI recovered from the lungs plus trachea on day 7 after instillation was >100 times the number originally inoculated. Later, however, the number of recovered bacteria diminished gradually, and by day 14 it was almost identical to the original inoculum size. Serum IgM also peaked on day 7 after infection, after which IgG increased while IgM decreased. Histologically, bronchoalveolar infiltration of neutrophils was observed on day 3 after inoculation and continued at least for the following 4 days. The present experiment demonstrates that MFL cells can protect bacteria that have invaded the cells from the opsonizing and killing activities of host humoral defense mechanisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985222     DOI: 10.1093/infdis/175.1.205

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Zyxin modulates the transmigration of Haemophilus influenzae to the central nervous system.

Authors:  Yuko Miyazaki; Takashi Yusa; Saburo Matsuo; Yasuo Terauchi; Shuichi Miyazaki
Journal:  Virulence       Date:  2014-07-15       Impact factor: 5.882

2.  In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.

Authors:  S Yoshizumi; H Domon; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections.

Authors:  S Miyazaki; H Domon; K Tateda; A Ohno; Y Ishii; T Matsumoto; N Furuya; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 4.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.

Authors:  K Yamaguchi; H Domon; S Miyazaki; K Tateda; A Ohno; K Ishii; T Matsumoto; N Furuya
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.

Authors:  S Miyazaki; T Hosoyama; N Furuya; Y Ishii; T Matsumoto; A Ohno; K Tateda; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  H Okamoto; S Miyazaki; K Tateda; Y Ishii; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Comparative efficacies of different antibiotic treatments to eradicate nontypeable Haemophilus influenzae infection.

Authors:  Yukie Sekiya; Masahiro Eguchi; Masahiko Nakamura; Kimiko Ubukata; Satoshi Omura; Hidenori Matsui
Journal:  BMC Infect Dis       Date:  2008-02-07       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.